Page 833 - ACCCN's Critical Care Nursing

810 I N D E X

renal replacement therapy (RRT) 788 hypercapnoeic 353–354 pulse oximetry 339–340, 340f
approaches to 491–501, 491f hypoxaemic 353, 354f ventilation 341
for ARF 488–490, 488b independent nursing practice 354–355 pandemics 360–362
continuous see continuous renal replacement NIV for 390 influenza 360
therapy oxygen maintenance and 354–355 isolation precautions and 362
convection 491–492 pathophysiology of 353–354 PPE and 362, 362t
diffusion 492 secondary to fluid aspiration 613f SARS 360–361
haemodiafiltration 491–492 type I 352–353, 354f pathophysiology 333–335
haemodialysis 491–492 type II 353–354 hypoxaemia 333–334, 334f
haemofiltration 491–492 post-anaesthesia support 357 inflammation 334
mode abbreviations for 491, 491t ventilation maintenance and 354–355 pulmonary oedema 334–335
refinement of 490–491 respiratory muscle innervation by cord pregnancy physiology adaptation of 713
ultrafiltration 492 level 556t breathing 713
renal system respiratory patterns 337t postpartum 713
anatomy of 480–483 brainstem injury and 449, 450f thorax 713
filtrate reabsorption 481f, 497–498 respiratory presentations, in ED 589–591 upper airway 713
GFR regulation 481f, 497–498 acute respiratory failure 591 pulmonary volumes and capacities 330–331,
glomerulus 480, 481f asthma 590, 591t 330f
kidneys 480, 480f pneumonia 591 alveolar ventilation 331
nephron 480, 480f–481f respiratory rate 392t, 393 support, for cardiogenic shock 550
urinary drainage system 480, 480f respiratory system ventilation control 328–330
urine production 481–482, 481f acid-base control 333 controller 328–329, 329f
hormonal and neural regulation in 482–483 alterations effectors 329
acid-base regulation 483, 483f case study 374b–375b sensors 329–330, 329f
ADH 482 incidence of 352–353, 353t work of breathing 331
ANP 483 anatomy of 326f, 328 responsible research practices 95
electrolyte balance 483 bronchial circulation 328 data use and disclosure 95
endocrine organ role 483 lower respiratory tract 326 ethics in publication 95
RAAS 482–483, 482f lungs 326–328, 327f resting potential 183–184
SNS 482 pleura 326–328, 328f restrictive cardiomyopathy (RCM) 242
liver transplantation and 524 pulmonary circulation 328, resuscitation 788
physiology of 480–483 328f–329f fluid see fluid resuscitation
pregnancy physiology adaptation of surfactant 326 injury to children and 700–701
713–714 thorax 326–328 SCI and 461
postpartum 714 upper respiratory tract 325–326, 327f SE and 470–471
renin-angiotensin-aldosterone system assessment 335–339 see also cardiopulmonary resuscitation
(RAAS) 190, 482–483, 482f auscultation 338–339, 338f, 339t reticular activation system (RAS) 421t–422t
heart failure and 228–229 current respiratory problems 335 retrieval 788
reperfusion therapy 221–224 documentation and charting 339 return of spontaneous circulation (ROSC) 788
research 11–12 family history 336 rhabdomyolysis 630
decision making in critical care nursing history-taking 335–336 Rhesus disease 733, 735t
8t–9t, 567–569 inspection 336–337, 337t rhythm
ethics in see ethics palpation 337–338, 338f post cardiac surgery, monitoring of 297
qualitative 11 personal history 336 sinus 252, 255f
quantitative 11 physical examination 336–339 strip 312f
responsible practices see responsible research previous respiratory problems 335 see also arrhythmias
practices symptoms 335–336 rib fractures 636
on RRS 52t bedside and laboratory investigations Richards Campbell Sleep Questionnaire
steps 11t 341–344 (RCSQ) 146, 146t
unconscious persons and 95 arterial blood gases 341–344 Richmond Agitation-Sedation Scale (RASS) 139,
Research and Ethical Boards (REBs) 91–92 blood tests 344 140f, 141t
research participant 788 nasopharyngeal aspirates 344 RIFLE criteria see risk, injury, and failure criteria
resistance 388–389 sputum sample 344 with outcomes of loss and end-stage
resources, ethical allocation and utilisation tracheal aspirates 344 renal disease
of 17–18 case study 348b right coronary artery (RCA) 182, 183f, 217
resourcing critical care services in children 682–683 right ventricular dysfunction, post heart
budget 20–22 compromise of, liver failure and 519 transplantation 316, 318t
case study 34b diagnostic procedures 344–347 right ventricular ejection fraction (RVEF) 203
economic considerations and principles bronchoscopy 347 right ventricular end-diastolic volume
19–20 chest x-ray 344–345, 345f, 346t (RVEDV) 203
equipment 22–23 CT 346 right ventricular end-diastolic volume index
historical influences 18–19 medical imaging 344–347 (RVEDVI) 203
pandemic management 33–34 MRI 347 right ventricular end-systolic volume
risk management 28–30 ultrasound 345–346 (RVESV) 203
staffing 23–28 V/Q scan 347 right ventricular end-systolic volume index
workload measures 30–33 disorders of see specific disorder (RVESVI) 203
respect for persons 788 dysfunction 371–373 right ventricular failure (RVF) 230–231, 230t
respiratory centres 329f gas transport principles 331–332 right ventricular stroke work index (RVSWI) 203
respiratory failure 353–357 carbon dioxide 332 rise time 392t, 394
acute 591 oxygen 331 risk 788
aetiology of 353 oxygen-haemoglobin dissociation risk, injury, and failure criteria with outcomes
clinical manifestations of 354 curve 331–332, 332f of loss and end-stage renal disease
collaborative practice 356, 356t V/Q ratio 332, 333f (RIFLE criteria) 486–487, 487f
medications 356 liver transplantation and 524 risk assessment scores 50–51, 51t
comorbidities and 356–357 monitoring of 339–341 risk management 28–30
elderly and 356 capnography 340–341, 341f clearly defined policies 29b